Skip to content
    BNTX
    Earnings call· Mar 2026(Q1 FY26)

    BioNTech SE Q1 FY26 earnings call BNTX

    May 5, 2026 Source

    Executive summary

    BioNTech Q1 FY26 — Oncology Pipeline Advancement and Share Buyback

    BioNTech continues to advance its oncology pipeline, focusing on combination therapies and late-stage assets like Pumitamig and Gotistobart, with several key data readouts expected in 2026. Despite a decline in Q1 COVID-19 vaccine revenues, the company reaffirmed its full-year guidance, supported by a strong balance sheet and a newly announced $1 billion share repurchase program. Strategic operational efficiency measures are also underway to optimize manufacturing and support future oncology commercialization.

    Highlights

    5

    • Pumitamig monotherapy in advanced NSCLC (PD-L1 >= 1%) showed a confirmed objective response rate of 46% and median progression-free survival of 13.6 months.

    • Gotistobart reduced the risk of death by 54% (HR 0.46) and achieved a 12-month PFS rate of 25% vs 0% for docetaxel in IO-pretreated metastatic squamous NSCLC.

    • Trastuzumab Permian Tian (TPAM) demonstrated a confirmed objective response rate of 49% and median duration of response of 9.9 months in HER2-expressing endometrial cancer.

    • Ended the quarter with a strong financial position of $16.8 billion in cash, cash equivalents, and security investments.

    • Initiated a share repurchase program of up to $1 billion over the next 12 months, reflecting confidence in the business.

    Concerns

    3

    • Q1 FY26 revenues decreased to $118 million from $183 million in the prior year, primarily due to lower COVID-19 vaccine demand.

    • Anticipate lower COVID-19 vaccine revenues for full year 2026 compared to 2025, driven by declines in both the United States and European markets.

    • Manufacturing footprint consolidation will affect just over 1,800 positions, with divestment options explored through the end of 2026.

    Guidance & targets

    6
    CategoryTargetConfidence
    Total Revenues
    $2.0B-$2.3B
    high materiality
    High
    Adjusted R&D Expenses
    $2.2B-$2.5B
    medium materiality
    High
    Adjusted SG&A Expenses
    $700M-$800M
    medium materiality
    High
    Share Repurchase Program
    up to USD 1 billion
    high materiality
    High
    Recurring Annual Savings from Manufacturing Consolidation
    $500 million
    medium materiality
    Medium
    BMS Collaboration Payment Recognition
    $613 million
    medium materiality
    High

    Segment performance

    4
    SegmentRevenueYoYQoQMargin
    Lung Cancer
    Phase Ib/IIa data for Pumitamig monotherapy in previously untreated advanced non-small cell lung cancer, enrolling both squamous and non-squamous histologies, showed encouraging results.
    Pumitamig Monotherapy ORR (PD-L1 >= 1%): 46%Pumitamig Monotherapy mPFS (PD-L1 >= 1%): 13.6 monthsPumitamig Monotherapy mOS (PD-L1 >= 1%): 27 monthsPumitamig Monotherapy DCR (PD-L1 >= 1%): 96%Pumitamig Monotherapy ORR (PD-L1 high squamous disease): 71%
    		————
    Squamous Non-Small Cell Lung Cancer
    Updated data from the nonpivotal dose confirmation stage of Preserve-003 for Gotistobart in IO pretreated metastatic squamous non-small cell lung cancer showed durable disease control and improved survival.
    Gotistobart 12-month PFS rate vs docetaxel: 25% vs 0%Gotistobart risk of death reduction vs docetaxel: 54%Gotistobart HR vs docetaxel: 0.46Gotistobart median OS: not yet reachedDocetaxel median OS: ~10 monthsGotistobart 12-month alive rate vs docetaxel: 63% vs 30%
    		————
    Gynecologic Cancers
    Updated data for Trastuzumab Permian Tian (TPAM) in HER2-expressing previously treated advanced or metastatic endometrial cancer, including patients who had received prior immunotherapy.
    TPAM ORR (HER2-expressing endometrial cancer): 49%TPAM mDoR (HER2-expressing endometrial cancer): 9.9 monthsTPAM DCR (HER2-expressing endometrial cancer): 79%
    		————
    Pancreatic Ductal Adenocarcinoma (PDAC)
    Updated long-term follow-up data from the PDAC Phase I trial for autogenevumiran, showing persistent cytotoxic cancer killing lymphocytes in immune responders.
    Autogenevumiran Phase I (immune responders) 6-year alive rate: 7 of 8 patientsAutogenevumiran Phase I (non-responders) median OS: 3.4 years
    		————

    Operational metrics

    9
    Total Revenues
    $118Mdown from $183M YoY
    Q1 FY26

    Primarily driven by lower demand from COVID-19 vaccines.

    Adjusted R&D Expenses
    $527Mvs $526M prior year period (IFRS)
    Q1 FY26

    Increase driven by higher spending on immuno-oncology and ADC programs (Pumitamig, Gotistobart) and BioNTech China acquisitions, partly offset by lower COVID-19 vaccine collaboration expenses.

    Adjusted SG&A Expenses
    $151Mvs $121M prior year period
    Q1 FY26

    Increase driven by ongoing commercial buildup and post-acquisition inclusion of BioNTech China operations.

    Cash, Cash Equivalents and Security Investments
    $16.8B
    Q1 FY26 end

    Strong financial position supporting pipeline investment and commercialization.

    Share Repurchase Program Authorization
    $1B
    next 12 months

    Program for American depositary shares, reflecting confidence and opportunistic flexibility.

    Recurring Annual Savings from Manufacturing Consolidation
    $500M
    annual

    Expected savings from optimizing operational efficiency and manufacturing footprint consolidation, intended to support oncology pipeline advancement.

    BMS Collaboration Payment Recognition
    $613M
    Q3 FY26

    Expected recognition of payment.

    COVID-19 Vaccine Revenue Pacing
    similar to last year's
    FY26

    Last 4 months of the year expected to drive the majority of full year revenue.

    Positions Affected by Manufacturing Consolidation
    just over 1,800
    ongoing

    Exploring divestment options for manufacturing sites.

    Deals & partnerships

    6
    [Bringelly]Collaboration to combine DLL3 targeting T cell engager with Pumitamig.

    The clinical trial aims to develop a novel treatment regimen that delivers more sustained tumor control in extensive stage small cell lung cancer.

    OncoSpanCollaboration for Gotistobart (selective Treg modulator targeting CTLA-4).

    Gotistobart is developed in collaboration with OncoSpan.

    [indiscernible]Collaboration for Trastuzumab Permian Tian (HER2-targeted ADC).

    TPAM is developed in collaboration with this partner.

    Roche GenentechPartnership for autogenevumiran (personalized mRNA immunotherapy).

    Autogenevumiran is partnered with Roche Genentech.

    PfizerCOVID-19 vaccine collaboration.

    Pfizer will fully handle supply of COVID-19 vaccine beginning at the end of 2026.

    BMS (Bristol-Myers Squibb)Collaboration on Pumitamig commercialization.

    Very deep and strong governance ongoing with BMS at different levels (scientific, clinical, commercial) for Pumitamig strategy.

    Risks & headwinds

    5
    Lower demand for COVID-19 vaccinesQ1 FY26 and full year 2026

    Q1 FY26 revenues $118M vs $183M YoY; FY26 total revenues expected lower than FY25.

    Mitigation: Defending market share in Europe, managing transition from multiyear contracts, focusing on oncology pipeline.

    Competitive and dynamic US COVID-19 vaccine marketOngoing

    N/A

    Mitigation: N/A

    Transition away from multiyear COVID-19 vaccine contracts in EuropeOngoing

    N/A

    Mitigation: Defending market share.

    Direct impact of declining COVID-19 vaccine sales in Germany on top lineFY26

    N/A

    Mitigation: N/A

    Manufacturing footprint consolidation affecting positionsThrough end of 2026

    Just over 1,800 positions affected.

    Mitigation: Exploring divestment options (partial or total sale) for manufacturing sites.

    What to watch in Q2 FY26

    5

    Phase III interim data for Gotistobart (Preserve-003)

    Later this year
    CurrentEncouraging nonpivotal data (12-month PFS 25% vs 0%, HR 0.46 for OS).
    TargetPositive interim readout from pivotal stage.

    Why it matters

    This program reinforces the breadth and depth of BioNTech's lung cancer pipeline and could provide further validation for a treatment in a setting with very few effective options.

    Based on current event accrual projections, we expect interim data from the pivotal stage of Preserve-003 later this year.

    Q&A highlights

    5

    Rationale for changing the primary endpoint from dual PFS/OS to single PFS for the RecetaLANg-02 trial, including discussions with BMS and FDA.

    The change was made because PFS is a well-accepted endpoint in non-small cell lung cancer, expected to show the largest and earliest benefit. Allocating the full alpha to PFS ensures a statistically robust readout. OS remains a key secondary endpoint, and this regulatory path is well-trodden, allowing for approval even with delayed OS data.

    “We have made this change because PFS is a well-accepted endpoint in non-small cell lung cancer and is very large, and we expect the largest and earliest benefit a signal in this endpoint and wanted to make sure that we allocate the full alpha on this endpoint and have a statistically robust read out.”

    asked by Daina Graybosch · answered by Özlem Türeci

    2 min read6 chapters

    Detailed Narrative

    01

    Oncology Strategy and Pipeline Focus

    BioNTech is transitioning to a diversified multiproduct oncology company by 2030, targeting over 17 late-stage and pivotal readouts. The strategy centers on rationally designed therapeutic combinations, utilizing immunomodulators, ADCs, and mRNA cancer immunotherapy, with a shift from platform-centric to tumor-centric development in high-incidence cancers like lung and breast. This approach aims to maximize value for patients and shareholders.

    02

    Lung Cancer Program Highlights

    The lung cancer strategy is matrix-based, addressing disease stages, clinical/molecular subgroups, and treatment backbones with Pumitamig at its core. Encouraging Phase Ib/IIa data for Pumitamig monotherapy in NSCLC showed strong objective response rates and progression-free survival, supporting the ongoing global Phase III RecetaLANg-02 trial. A new collaboration with [Bringelly] combines a DLL3 targeting T cell engager with Pumitamig for extensive stage small cell lung cancer.

    03

    Gotistobart Progress in Squamous NSCLC

    Gotistobart, a selective Treg modulator, received orphan drug designation from the FDA for squamous NSCLC, building on its existing fast track designation. Updated data from the nonpivotal dose confirmation stage of Preserve-003 showed durable disease control and a significant reduction in the risk of death in IO-pretreated metastatic squamous NSCLC. Interim data from the pivotal stage of Preserve-003 are expected later this year.

    04

    Gynecologic Cancers and TPAM Development

    Trastuzumab Permian Tian (TPAM), an HER2-targeted ADC, demonstrated strong efficacy with a high objective response rate and duration of response in HER2-expressing endometrial cancer, including across all HER2 expression levels. The confirmatory FRNC-01 Phase III trial continues to enroll, and a Phase III interim analysis for TPAM in HR-positive, HER2 low metastatic breast cancer (Dynasty BREAST 02) is anticipated later this year.

    05

    mRNA Immunotherapies and Collaborations

    BioNTech's personalized mRNA cancer immunotherapy, autogenevumiran (partnered with Roche Genentech), showed promising long-term follow-up data in PDAC Phase I, with immune responders demonstrating persistent cytotoxic cancer killing lymphocytes. Ongoing trials include a Phase II in adjuvant colorectal cancer and a Phase II/III for fixed rack in HPV16-positive HNSCC, with an interim analysis for the latter expected in 2026.

    06

    Capital Allocation and Operational Efficiency

    BioNTech's capital allocation strategy prioritizes R&D investments in its pipeline, a newly announced $1 billion share repurchase program, and optimizing operational efficiency. The company plans to consolidate its manufacturing footprint, affecting over 1,800 positions, aiming for $500 million in recurring annual savings to further support oncology pipeline advancement and commercialization.

    AI-generated summary of the company’s earnings call. Not investment advice.